UPCC 15424 Second Malignancies in Patients treated with CAR T-cell Therapy

Enrolling By Invitation
99 years or below
All
Phase N/A
20 participants needed
1 Location

Brief description of study

To explore secondary malignancies in subjects enrolled to the L-RAD study (IRB #832203, Lymphoproliferative Disorders: Biological Specimen Repository and Clinical Database) who received CAR T-cells or other T-cell directed therapies for lymphoproliferative disorders and to investigate potential relationships between prior T-cell directed therapy for lymphoma and subsequent malignancies.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

Updated on 22 Apr 2026. Study ID: 23-1787
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator